Acalabrutinib
Tier A — Act nowAcalabrutinib · all drugs expiring in 2030 →
Targets：BTK
Brand：Calquence
Indications (approved)：Mantle cell lymphoma, Chronic lymphocytic leukaemia, Lymphocytic leukaemia
Regional status
Synthetic routes & intermediates2 routes
Routes are ordered originator first, then optimised / process (non-patent) routes; each lists steps, overall yield and the intermediate table (code / CAS / name) — ready for supplier sourcing and RFQ. Rendered by this site from structured data; no third-party route graphics used.
| Code | CAS No. | Intermediate |
|---|---|---|
| ACAT-001 | 55557-52-3Available | 3-chloropyrazine-2-carbonitrile |
| ACAT-002 | 939412-86-9Available | (3-chloropyrazin-2-yl)methanamine hydrochloride |
| ACAT-003 | 1148-11-4Available | ((benzyloxy)carbonyl)-L-proline |
| ACAT-004 | 1418307-17-1Available | benzyl (S)-2-(((3-chloropyrazin-2-yl)methyl)carbamoyl)pyrrolidine-1-carboxylate |
| ACAT-005 | 1418307-18-2Available | benzyl (S)-2-(8-chloroimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate |
| ACAT-006 | 1420478-87-0Available | benzyl (S)-2-(1-bromo-8-chloroimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate |
| ACAT-007 | 1420478-88-1Available | benzyl (S)-2-(8-amino-1-bromoimidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate |
| ACAT-008 | 850568-25-1Available | N-(pyridin-2-yl)-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzamide |
| ACAT-009 | 1420478-89-2Available | benzyl (S)-2-(8-amino-1-(4-(pyridin-2-ylcarbamoyl)phenyl)imidazo[1,5-a]pyrazin-3-yl)pyrrolidine-1-carboxylate |
| ACAT-010 | 1420478-90-5Available | (S)-4-(8-amino-3-(pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide |
| ACAT-011 | 590-93-2Available | 4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)benzoic acid |
| Code | CAS No. | Intermediate |
|---|---|---|
| ACAT-012 | 586-76-5Available | 4-bromobenzoic acid |
| ACAT-013 | 504-29-0Available | pyridin-2-amine |
| ACAT-014 | 121246-96-6Available | (4-(pyridin-2-ylcarbamoyl)phenyl)boronic acid |
| ACAT-015 | - | 3-chloropyrazine-2-carbaldehyde |
| ACAT-016 | - | 4-(amino(3-chloropyrazin-2-yl)methyl)-N-(pyridin-2-yl)benzamide |
| ACAT-017 | - | but-2-ynoyl-L-proline |
Frequently asked questions
What are the approved indications of Acalabrutinib?
Approved indications include: Mantle cell lymphoma, Chronic lymphocytic leukaemia, Lymphocytic leukaemia.
When does the Acalabrutinib patent expire?
Based on public sources, the Acalabrutinib patent expires in 2030.
How many synthesis routes are recorded for Acalabrutinib?
2 synthesis routes are recorded; the shortest is 4 steps with 0.4 g (Acalabrutinib) total yield. Intermediates in each route carry codes and CAS numbers.
Where can I buy Acalabrutinib intermediates?
14 intermediate CAS of Acalabrutinib are available through the Unibest supply network — see the route tables on this page and request a quote per CAS.
How do I get a quote for Acalabrutinib intermediates?
Open the CAS profile of the target intermediate from this page, or submit an RFQ directly — the CAS enters the matching flow automatically and the supply network responds with quotes.
Source: cross-verified data (structured fields only) · 2026-09-29